НАРУШЕНИЕ УГЛЕВОДНОГО ОБМЕНА У БОЛЬНЫХ ПОСЛЕ ПЕРЕНЕСЕННОЙ КОРОНАВИРУСНОЙ ИНФЕКЦИИ
Ключевые слова:
COVID-19, SARSCoV-2, сахарный диабет, ожирение.Аннотация
Пандемия COVID-19 продолжается по всему миру. В настоящее время подтверждено около 590 миллионов случаев и 6,44 миллиона смертей. Ведется интенсивная работа по борьбе с этим заболеванием, предотвращая распространение вируса, изучая его патогенез, создавая вакцины для профилактики, планы лечения и определяя цели лечения. Ранее диагностированные люди с диабетом имеют более сложное течение COVID-19 и худшие прогнозы. Кроме того, после того, как пациентам поставили диагноз COVID-19, у них были высокие показатели диабета, а также новые зарегистрированные случаи сахарного диабета. Пациенты, у которых раньше не диагностировали диабет, подвержены большему риску развития гипергликемии и других осложнений из-за COVID-19. Цель этого обзора состоит в том, чтобы обобщить то, что мы знаем об эпидемии COVID-19 и о том, как она связана с диабетом в двух направлениях.
Библиографические ссылки
WHO. WHO Coronavirus Disease (COVID-19) Dashboard. [cited 8 August 2022]. Available from: https://covid19.who.int/
Wu, Z.; McGoogan, J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreakin China: Summary of a Report of 72314 сases from the Chinese Center for Disease Control and Prevention. JAMA.2020; 323: 1239–1242.
Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020; 8:782–792.
Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021; 17: 11-30.
Rubino F, Amiel SA, Zimmet P, et al. New-onset diabetes in Covid-19. NEngl J Med. 2020;383:789–790.
Dhan Bahadur Shrestha, Pravash Budhathoki, Sumit Raut, Sugat Adhikari, Prinska Ghimire, Sabin Thapaliya, Ali A Rabaan, Bibodh Jung Karki. New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World J Virol. 2021; 10(5): 275-287.
Barbu MG, Thompson RJ, Thompson DC, Cretoiu D, Suciu N. The impact of SARS-CoV-2 on the most common comorbidities-a retrospective study on 814 COVID-19 deaths in Romania. Front Med (Lausanne). 2020;7:567199.
Erener S. Diabetes, infection risk and COVID-19. Mol Metab. 2020;39:101044
Shi Q, Zhang X, Jiang F, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. Diabetes Care. 2020;43:1382–1391.
Selvin E, Juraschek SP. Diabetes epidemiology in the COVID-19 pandemic. Diabetes Care. 2020;43:1690–1694.
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence,pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr . 2020;14:303–310.
Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8:813–822.
Accili D. Can COVID-19 cause diabetes? Nat Metab. 2021;3:123–125.
Li J,Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab 2020;22: 1935–1941.
Rawla P, Bandaru SS, Vellipuram AR. Review of infectious etiology of acute pancreatitis. Gastroenterol Res 2017;10:153–158.
Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020;369:m1966.
Al-Sabah S, Al-Haddad M, Al-Youha S, Jamal M, Almazeedi S. COVID-19: impact of obesity and diabetes on disease severity. Clin Obes. 2020;10:e12414.
Khunti K, Del Prato S, Mathieu C, et al. COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care. 2021; 44(12):2645-2655.
Sathish T, Kapoor N, Cao Y, et al. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes Metab. 2021; 23(3):870-874.
Shrestha DB, Budhathoki P, Raut S et al. New- onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World J Virol. 2021; 10(5):275-287.
Lazarus G, Audrey J, Wangsaputra VK, et al. High admission blood glucose independently predicts poor prognosis in COVID-19 patients: A systematic review and dose-response meta-analysis. Diabetes Res Clin Pract. 2021; 171:108561.
Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8:782–792.
Yang JK, Jin JM, Liu S, et al. New onset COVID-19–related diabetes: an indicator of mortality. Med Rxiv. 2020 [preprint]. DOI: 0.1101/2020.04.08.20058040.
Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020; 22:1897–1906.
Wang S, Ma P, Zhang S, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia 2020;63:2102–2111.
Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 11» / Министерство здравоохранения РФ. – Москва: МЗ РФ, 2021. –– 225 c.
Sharma, S. Metformin in COVID-19: a possible role beyond diabetes / S. Sharma, A. Ray, B. Sadasivam // Diabetes Research and Clinical Practice. – 2020. – № 164. – P.108183.
Мetformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction / J. Kim, H.J. Kwak, J.Y. Cha [et al.] // Journal of Biological Chemistry. – 2014. – Vol. 289, № 33. – P.23246–23255.
Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study / R. Roussel, P. Darmon, M. Pichelin [et al.] // Diabetes Obesity Metabolism. – 2021. – № 23. – P.1162.
No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19 / J.H. Zhou, B. Wu, W.X. Wang [et al.] // World Journal of Clinical Cases. – 2020. –№ 8. – P.5576.
Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial / D. Athauda [et al.] // Lancet. – 2017. – № 390. – P.1664–1675.
Glucose – lowering therapies in patients with type 2 diabetes and cardiovascular diseases / F. Prattichizzo [et al.] // European Journal of Preventive Cardiology. – 2019. – № 26. – P.73–80.
Practical recommendations for the management of diabetes in patients with COVID-19 / S.R. Bornstein, F. Rubino, K. Khunti [et al.] // Lancet Diabetes Endocrinology. – 2020. – Vol. 8, № 6. – P.546–550.
Cure, E. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis / E. Cure, C.M. Cure // Diabetes & Metabolic Syndrome. – 2020. – № 14. – P.405–406.
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study / M. Kosiborod [et al.] // Diabetes Obesity Metabolism. – 2021. – Vol. 23, №.4. – P.886-896.
Acute kidney injury from SGLT2 inhibitors: potential mechanisms / K. Hahn, A.A. Ejaz, M. Kanbay [et al.] // Nature Reviews Nephrology. – 2016. – Vol. 12, № 12. – P.711–712.
Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 / C. Ciavarella, I. Motta, S. Valente, G. Pasquinelli // Disease. Molecules. – 2020. – Vol. 25, № 9. – P.2076.
Pioglitazone after ischemic stroke or transient ischemic attack / W.N. Kernan [et al.] // The New England Journal of Medicine. – 2016. – № 374. – P.1321–1331
